our other indications

Atopic Dermatitis (AD), Eczema – JEL0305

Atopic dermatitis (AD) is a disease of unknown origin that usually starts in early infancy and is typified by pruritis (itch), eczematous lesions, xerosis (dry skin) and lichenification of the skin, which is thickening of the skin and an increase in skin marking. It is the most common skin disease in children, affecting approximately 15% – 20% of children and 1% – 3% of adults (Nutten S, 2015; Eichenfield LF et al, 2014).

The onset of the disease is often by 5 years of age, with the highest incidence occurring between the ages of 3 and 6 months although it can occur at any age (Eichenfield LF et al, 2014, Hanifin JM et al, 2007). Early diagnosis and treatment are essential to avoid complications of AD and improve quality of life (Eichenfield LF et al, 2014). The current treatments for AD carry significant safety liabilities, which mostly limit their application to moderate-to-severe AD patients.

Carocell Bio’s JEL0305 peptide, delivered as a topical formulation (cream/ointment) is expected to become the first line treatment for AD because of its safety and efficacy.

Inflammatory bowel disease (IBD) – JEL2603

Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of the digestive tract.

Due to its chronic and unpredictable disease course, young age of onset, and the need for life-long, and lack of suitable therapies, IBD is an important global public health problem. As curative treatments are lacking, the incidence and prevalence of the disease are increasing.  The current medical approach for patients with IBD is symptomatic care and mucosal healing and follows a stepwise medication approach, escalating the medical regimen until a response is achieved. In addition, several IBD treatments, including end-stage injected biologics, have a number of contraindications and side effects, including opportunistic infections and malignancies.

Currently an estimated 2.5–3 million people in Europe are affected by IBD, with direct healthcare costs estimated to be EUR €4.6–5.6 billion per year. In the US there is a prevalence of 238 per 100,000 adults and the number of ulcerative colitis patients are increasing in emerging economies.

Carocell Bio’s JEL2603 peptide provides a safe, convenient, and efficacious topical alternative to existing injected biologics, especially when delivered as a topical gel formulation. It would be able to target all severities of IBD, with the prospect of treating flares as well as being used for long-maintenance.

Epidermolysis Bullosa – JEL1103

Epidermolysis bullosa (EB) is the name for a group of rare, inherited (genetic) skin disorders that cause the skin to become very fragile. It is characterised by a lack of adhesion of the skin directly above the basement membrane (the basal layer). Any trauma or friction to the skin can cause painful blisters. Painful open wounds and sores form where this exceptionally fragile skin is damaged, and in some cases internal linings and organs are also affected.

Complications as a result of secondary infection and extensive scarring are factors that people living with EB often have to face. Tragically, certain types of EB can be fatal in infancy and others are severely life-limiting. It is estimated that more than 5,000 people are living with EB in the UK, and 500,000 worldwide.

There is no known cure for EB. Treatments are limited to pain relief, antibiotics for infected blisters and surgery. Topical steroids are used to limit inflammation, however their use is limited due to a poor safety profile and cannot be used in the long term.

This is an opportunity for JEL1103 to be used as an easily applied, safe, topical anti-inflammatory treatment. 

OUR RESEARCH

Find out more about our therapeutic peptides and how they can reduce inflammation in a host of serious inflammatory diseases.

PRESENTATION SLIDES

For further information and access to detailed documentation, please get in touch.